Literature DB >> 21224460

Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.

Lisa G Rider1, Frederick W Miller.   

Abstract

The idiopathic inflammatory myopathies or myositis syndromes (the most common forms are polymyositis, dermatomyositis, and inclusion body myositis) are systemic autoimmune diseases defined by chronic muscle weakness and inflammation of unknown etiology and result in significant morbidity and mortality. Research suggests that categorizing heterogeneous myositis syndromes into mutually exclusive and stable phenotypes by using clinical and immune response features is useful for predicting clinical signs and symptoms, associated genetic and environmental risk factors, and responses to therapy and prognosis. Knowledge of myositis phenotypes should enhance clinicians' ability to recognize and manage these rare disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21224460      PMCID: PMC4047218          DOI: 10.1001/jama.2010.1977

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  48 in total

1.  Immunoprecipitation-western blot for proteins of low abundance.

Authors:  Edward P Trieu; Joanne K Gross; Ira N Targoff
Journal:  Methods Mol Biol       Date:  2009

Review 2.  Defining cancer risk in dermatomyositis. Part I.

Authors:  V Madan; H Chinoy; C E M Griffiths; R G Cooper
Journal:  Clin Exp Dermatol       Date:  2009-04-14       Impact factor: 3.470

3.  RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease.

Authors:  Shinji Sato; Kana Hoshino; Takashi Satoh; Tomonobu Fujita; Yutaka Kawakami; Takashi Fujita; Masataka Kuwana
Journal:  Arthritis Rheum       Date:  2009-07

4.  Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia.

Authors:  Aryeh Fischer; Jeffrey J Swigris; Roland M du Bois; David A Lynch; Gregory P Downey; Gregory P Cosgrove; Stephen K Frankel; Evans R Fernandez-Perez; JoAnn Z Gillis; Kevin K Brown
Journal:  Respir Med       Date:  2009-06-03       Impact factor: 3.415

5.  Genetic risk and protective factors for the idiopathic inflammatory myopathies.

Authors:  Terrance P O'Hanlon; Frederick W Miller
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

Review 6.  Treatment of the inflammatory myopathies: update and practical recommendations.

Authors:  Gerald J D Hengstman; Frank H J van den Hoogen; Baziel G M van Engelen
Journal:  Expert Opin Pharmacother       Date:  2009-05       Impact factor: 3.889

7.  Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index.

Authors:  Lisa G Rider; Peter A Lachenbruch; Jason B Monroe; Angelo Ravelli; Imelda Cabalar; Brian M Feldman; Maria L Villalba; Barry L Myones; Lauren M Pachman; Robert M Rennebohm; Ann M Reed; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2009-11

8.  Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women.

Authors:  Lori A Love; Clarice R Weinberg; D Robert McConnaughey; Chester V Oddis; Thomas A Medsger; John D Reveille; Frank C Arnett; Ira N Targoff; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2009-08

Review 9.  Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.

Authors:  Lucy R Wedderburn; Lisa G Rider
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-10       Impact factor: 4.098

10.  Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

Authors:  Marinos C Dalakas; Goran Rakocevic; Jens Schmidt; Mohammad Salajegheh; Beverly McElroy; Michael O Harris-Love; Joseph A Shrader; Ellen W Levy; James Dambrosia; Robert L Kampen; David A Bruno; Allan D Kirk
Journal:  Brain       Date:  2009-05-19       Impact factor: 13.501

View more
  42 in total

Review 1.  Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop.

Authors:  Frederick W Miller; Lars Alfredsson; Karen H Costenbader; Diane L Kamen; Lorene M Nelson; Jill M Norris; Anneclaire J De Roos
Journal:  J Autoimmun       Date:  2012-06-25       Impact factor: 7.094

Review 2.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

3.  Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis.

Authors:  Mona Shah; Ira N Targoff; Madeline M Rice; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2013-07

Review 4.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

Review 5.  Myositis Mimics.

Authors:  E Harlan Michelle; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592

6.  Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.

Authors:  Richard M Yeker; Iago Pinal-Fernandez; Lisa G Rider; Andrew L Mammen; Takayuki Kishi; Katherine Pak; Ira N Targoff; Frederick W Miller
Journal:  Ann Rheum Dis       Date:  2018-01-23       Impact factor: 19.103

7.  Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.

Authors:  Thomas E Lloyd; Lisa Christopher-Stine; Iago Pinal-Fernandez; Eleni Tiniakou; Michelle Petri; Alan Baer; Sonye K Danoff; Katherine Pak; Livia A Casciola-Rosen; Andrew L Mammen
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-01       Impact factor: 4.794

Review 8.  Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review.

Authors:  Eleni Tiniakou; Andrew L Mammen
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

9.  Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients.

Authors:  Hang Zhou; Yunchao Wang; Kuo Bi; Haiyu Qi; Shuju Song; Mingzhu Zhou; Letian Chen; Guochun Wang; Ting Duan
Journal:  Clin Rheumatol       Date:  2019-01-15       Impact factor: 2.980

10.  Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study.

Authors:  Cécile Picard; Thierry Vincent; Jean-Christophe Lega; Sophie Hue; Françoise Fortenfant; Daniela Lakomy; René-Louis Humbel; Joelle Goetz; Nicolas Molinari; Nathalie Bardin; Daniel Bertin; Catherine Johanet; Pascale Chretien; Sylvain Dubucquoi; Nathalie Streichenberger; Sophie Desplat-Jégo; Xavier Bossuyt; Jean Sibilia; Isabelle Abreu; Alain Chevailler; Nicole Fabien
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.